14102 studies
This case report highlights the therapeutic efficacy of semaglutide in a 49-year-old male with concurrent type 2 diabetes mellitus (T2DM), psoriasis (PASI 22), and metabolic dysfunction-associated steatotic liver disease (MASLD). The patient presente…
INTRODUCTION: This report describes the percentage of adults with diagnosed diabetes who were taking an injectable glucagon-like peptide-1 (GLP-1) receptor agonist at the time of interview by selected characteristics, based on data from the 2024 Nati…
CONTEXT: There is emerging evidence suggesting a possible association between glucagon-like peptide-1 receptor agonists (GLP-1 RA) and non-arteritic anterior ischemic optic neuropathy (NAION). Retrospective cohort studies supporting this association…
PURPOSE: Large telehealth companies and smaller aesthetic medicine providers used compounded semaglutide and tirzepatide to meet consumer demand for these drugs during their shortages. In this study, we estimate the documentation rate of compounded f…
Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA) used to manage type 2 diabetes and, since 2021, for weight loss in individuals with obesity or weight-related comorbidities. It works by enhancing insulin secretion, delaying gastric…
AIMS: This study evaluated the metabolic efficacy of ForePass-a novel, incision-free, reversible, endoscopically delivered device that mimics biliopancreatic diversion-in growing pigs. The primary aim was the superiority of ForePass over Semaglutide…
INTRODUCTION: Semaglutide, available widely as Ozempic, Wegovy, and Rybelsus, has significantly improved the management of type 2 diabetes and obesity due to its beneficial adverse drug reactions and safer use in diverse population. However, as its u…
INTRODUCTION: Quantification of amyloid plaques (A), neurofibrillary tangles (T), and neurodegeneration (N) using PET and MRI is critical for Alzheimer's disease (AD) diagnosis and prognosis. Existing pipelines face limitations regarding processing t…
INTRODUCTION: Injectable formulations are common for protein-based therapeutics. However, non-injectable formulations are crucial for improving patient compliance. This study aims to develop hyaluronic acid/aminoclay-based dissolving microneedles as…
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used for type 2 diabetes mellitus (T2DM) due to their multifaceted benefits, including glycemic control and cardiovascular protection. However, variations in prescribin…
OBJECTIVE: This study aimed to identify clinical predictors associated with reductions in HbA1c and weight among patients with type 2 diabetes mellitus (T2DM) treated with semaglutide in real-world clinical settings in Bulgaria. METHODS: A retrospect…
This systematic review and network meta-analysis evaluated the efficacy and safety of obesity management medications (OMMs) in terms of reducing body weight and impact on obesity-related complications. Here a Medline and Embase search was performed u…
OBJECTIVE: This study aimed to characterize the reasons for treatment discontinuation with injectable semaglutide or tirzepatide for obesity in regular clinical practice. METHODS: This cross-sectional study used electronic health record data between…
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used to improve glycemic control and induce weight loss in individuals with type 2 diabetes (T2D), yet treatment responses vary significantly among individuals. Eating behavi…
BACKGROUND: Systematic and transparent evaluation of medicines remains a global challenge. In China, structured frameworks for clinical value assessment are underutilized despite improved access to negotiated medicines. Once-weekly glucagon-like pept…
Strategies to reduce weight in people living with obesity (PwO) include calorie restriction, metabolic and bariatric surgery (MBS), and anti-obesity drugs, including glucagon-like peptide-1 receptor agonists (GLP-1Ra). Although weight loss in PwO has…
BACKGROUND: Semaglutide is an effective antidiabetic agent that is injected weekly to induce weight reduction, and the impact on cardiovascular outcomes is favorable. OBJECTIVE: The aim was to evaluate the persistence of the use of weekly injectable…
BACKGROUND: Exercise function quantified by 6-minute walk distance (6MWD) is severely impaired in patients with heart failure with preserved ejection fraction (HFpEF). OBJECTIVES: This prespecified secondary analysis of pooled data from the STEP-HFpE…
While mitochondria provide critical energy resources, mitochondrial dysfunction can lead to both metabolic and neurodegenerative disorders. Primary mitochondrial disorders (e.g., Leigh syndrome) are uniformly associated with profound neurodegeneratio…